VBI Vaccines Inc
OTC:VBIVQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Minco Silver Corp
TSX:MSV
|
CA |
|
Y
|
Yidu Tech Inc
HKEX:2158
|
CN |
|
Ambassador Hotel Ltd
TWSE:2704
|
TW |
|
S
|
SNC Former PCL
SET:SNC
|
TH |
|
W
|
Wing Tai Properties Ltd
HKEX:369
|
HK |
|
T
|
Tennant Minerals Ltd
ASX:TMS
|
AU |
|
Jindalee Resources Ltd
ASX:JRL
|
AU |
|
S
|
Sparebank 1 SR Bank ASA
OSE:SRBNK
|
NO |
|
E
|
Enel Chile SA
SGO:ENELCHILE
|
CL |
|
De.mem Ltd
ASX:DEM
|
AU |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
VBI Vaccines Inc
NASDAQ:VBIV
|
808.8k USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.4B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
VBI Vaccines Inc
Glance View
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 149 full-time employees. The company went IPO on 2001-11-19. The firm develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The firm is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers including glioblastoma (GBM). Its PreHevbrio (Hepatitis B Vaccine [Recombinant]), which contains S, pre-S2, and pre-S1 HBV surface antigens and is an approved 3-antigen HBV vaccine for adults. Its Prophylactic candidates include VBI-2900, which is a coronavirus vaccine Program (VBI-2901, VBI-2902, VBI-2905); VBI-1501, which is prophylactic CMV vaccine candidate; VBI-2601, which is HBV Immunotherapeutic Candidate, and VBI-1901, which targets CMV proteins present in tumor cells. The firm is conducting the Phase I/IIa clinical study of GBM vaccine immunotherapeutic candidate VBI-1901.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for VBI Vaccines Inc is -767%, which is above its 3-year median of -3 340.4%.
Over the last 3 years, VBI Vaccines Inc’s Operating Margin has increased from -5 308.5% to -767%. During this period, it reached a low of -14 837% on Mar 31, 2022 and a high of -637.1% on Dec 31, 2023.
